Osteoporosis Treatment — Fracture Prevention and Bone Density Management — Cost, Top Hospitals & Success Rates | MyMedicPlus

Osteoporosis is a systemic skeletal disease characterised by reduced bone mineral density (BMD) and deterioration of bone microarchitecture, resulting in increased bone fragility and fracture risk. The World Health Organization (WHO) defines osteoporosis as a bone mineral density T-score of −2.5 standard deviations (SD) or below at the femoral neck, total hip, or lumbar spine on dual-energy X-ray absorptiometry (DXA). Osteopenia (low bone mass) is defined as T-score between −1.0 and −2.5 SD.

Osteoporosis is a major global health burden affecting approximately 200 million people worldwide. An estimated 1 in 3 women and 1 in 5 men over 50 will experience an osteoporotic fracture in their lifetime. Vertebral compression fractures are the most common (approximately 700,000 per year in the USA alone), followed by hip fractures — the most devastating, carrying 20–30% one-year mortality and 50% permanent loss of independence in elderly patients.

The critical insight in osteoporosis management is that the goal is fracture prevention, not simply T-score improvement. Treatment decisions are guided by the individual's absolute fracture risk — calculated using the FRAX tool (developed by WHO Collaborating Centre, University of Sheffield) — rather than T-score alone. FRAX integrates clinical risk factors (age, sex, BMI, prior fracture, parental hip fracture history, smoking, alcohol, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis) with or without BMD to calculate 10-year probability of major osteoporotic fracture and hip fracture, with country-specific intervention thresholds.

Modern pharmacological osteoporosis therapy encompasses antiresorptive agents (bisphosphonates, denosumab, selective oestrogen receptor modulators) and anabolic agents (teriparatide, abaloparatide, romosozumab), offering highly effective fracture risk reduction — up to 70–75% reduction in vertebral fractures with anabolic agents — when used in line with current guidelines from the National Osteoporosis Foundation (NOF), Royal Osteoporosis Society (ROS), ESCEO, and IOF.

Osteoporosis is classified as primary (postmenopausal and age-related) or secondary (caused by an identifiable underlying condition or medication):

Primary osteoporosis:

• Postmenopausal osteoporosis (Type I): The most common form, driven by oestrogen deficiency at menopause. Rapid bone loss of 2–3% per year occurs in the first 5–10 years post-menopause, predominantly affecting trabecular bone (vertebrae, distal radius).
• Age-related osteoporosis (Type II): Affects both men and women over 70; results from decreased osteoblast function, reduced calcium absorption, secondary hyperparathyroidism, and reduced physical activity. Affects both cortical and trabecular bone; hip fractures predominate.

Secondary osteoporosis (must be excluded in all patients, particularly men and premenopausal women):

• Glucocorticoid-induced osteoporosis (GIOP): The most common cause of secondary osteoporosis; systemic glucocorticoids at ≥5 mg prednisolone daily for ≥3 months significantly increase fracture risk even at normal BMD. ACR guidelines recommend preventive antiresorptive therapy in all patients on long-term steroids.
• Hypogonadism (male hypogonadism, premature ovarian insufficiency)
• Hyperparathyroidism (primary: adenoma; secondary: vitamin D deficiency)
• Hyperthyroidism and supraphysiological thyroid hormone replacement
• Coeliac disease and inflammatory bowel disease (malabsorption)
• Chronic kidney disease (renal osteodystrophy)
• Liver disease (alcoholic, primary biliary cholangitis)
• Diabetes mellitus Type 1 and Type 2 (elevated fracture risk despite sometimes normal BMD)
• Anorexia nervosa
• Haematological malignancies (myeloma — must be excluded with protein electrophoresis and serum free light chains)

All patients diagnosed with osteoporosis should undergo basic laboratory investigations to exclude secondary causes: full blood count, calcium, phosphate, alkaline phosphatase, renal and liver function, thyroid function, 25-hydroxyvitamin D, PTH, protein electrophoresis (in older adults), and sex hormones (testosterone in men) where appropriate.

The decision to initiate pharmacological osteoporosis treatment is based on absolute fracture risk stratification, not T-score alone. Current decision-making frameworks:

FRAX intervention thresholds: FRAX calculates the 10-year probability of major osteoporotic fracture (MOF: hip, clinical vertebra, forearm, or proximal humerus) and hip fracture. Country-specific thresholds for pharmacological intervention are published by national guideline bodies. In the UK (NICE CG146 and NOGG guidelines), treatment is recommended when:

• FRAX 10-year MOF probability exceeds the age-specific intervention threshold (e.g., approximately 7.5% MOF at age 50; higher thresholds at older ages where background population risk is higher)
• Or when a patient has suffered a fragility fracture (any fracture from a fall from standing height or less), particularly hip or vertebral — these patients are at very high re-fracture risk and should be treated promptly (within 12 weeks of fracture).

T-score-based treatment: Most international guidelines recommend treatment initiation at T-score ≤−2.5 SD in postmenopausal women and men ≥50, in the absence of FRAX data. In patients with prior hip or vertebral fracture (clinical or morphometric), treatment is indicated regardless of T-score.

Calcium and vitamin D status: Adequate calcium and vitamin D sufficiency is a prerequisite before commencing antiresorptive or anabolic therapy. Vitamin D level (>50 nmol/L or 20 ng/mL) should be confirmed; supplementation commenced if deficient. Routine calcium supplementation is not recommended for all patients (VITAL and RECORD trials showed no fracture benefit and potential cardiovascular risk in well-nourished individuals) — supplementation is targeted to those with dietary calcium intake <700 mg/day.

Sequential therapy planning: The risk of rebound vertebral fracture on discontinuing denosumab necessitates pre-planned transition to an antiresorptive agent (zoledronic acid or bisphosphonate) before or promptly after stopping denosumab — a critical consideration when selecting initial therapy in patients for whom long-term adherence or continuation may be uncertain.

1. Non-Pharmacological Foundations

Fall prevention is as important as pharmacological fracture prevention in frail older adults. Multifactorial falls assessment addressing home hazards, footwear, visual impairment, cardiac arrhythmias, and postural hypotension reduces falls by 20–30%. Weight-bearing exercise (walking, resistance training, balance and proprioception training — Tai Chi) maintains BMD and reduces falls risk. Smoking cessation and alcohol reduction (<3 units/day) reduce bone resorption.

2. Calcium and Vitamin D Supplementation

Supplementation is targeted to deficient patients rather than universal prescription. Recommended intakes: calcium 700–1,200 mg/day (from diet where possible); vitamin D 800–1,000 IU/day. The VITAL trial (NEJM, 2022) in 25,871 participants found no significant reduction in fracture risk with vitamin D3 supplementation in vitamin D-replete individuals, reinforcing that supplementation should be reserved for those with deficiency (25-OH vitamin D <50 nmol/L).

3. Antiresorptive Therapy — Bisphosphonates

Alendronate 70 mg weekly (oral) is the most extensively studied osteoporosis treatment. The FIT trial (Fracture Intervention Trial) demonstrated 47% reduction in vertebral fractures, 51% reduction in hip fractures, and 48% reduction in wrist fractures over 3 years. Alendronate is generic, widely available, and cost-effective. Must be taken fasting with a full glass of water, and the patient must remain upright for 30–60 minutes to minimise oesophageal adverse effects. Risedronate 35 mg weekly (BONE trial) offers similar vertebral fracture efficacy with slightly better GI tolerability. Ibandronate 150 mg monthly is approved for vertebral fracture prevention; evidence for non-vertebral and hip fracture reduction is less robust.

Intravenous zoledronic acid 5 mg annually is the most potent bisphosphonate, suitable for patients intolerant of or non-adherent to oral bisphosphonates. The HORIZON Pivotal Fracture Trial demonstrated 35% reduction in vertebral fractures, 27% reduction in hip fractures, and 25% reduction in non-vertebral fractures over 3 years. Also reduces mortality when given within 90 days of hip fracture repair (HORIZON Recurrent Fracture Trial). Post-first-dose acute phase reaction (flu-like symptoms, bone pain) occurs in 30% of patients but is self-limiting and preventable by pre-hydration and paracetamol.

4. Denosumab

Denosumab (Prolia) 60 mg subcutaneously every 6 months is a fully human monoclonal antibody inhibiting RANKL (receptor activator of NFkB ligand), thereby suppressing osteoclast formation and function. The FREEDOM trial demonstrated 68% reduction in vertebral fractures, 20% reduction in non-vertebral fractures, and 40% reduction in hip fractures over 3 years. FREEDOM Extension demonstrated sustained BMD gains for up to 10 years — unlike bisphosphonates, denosumab does not bind to bone and its effect is fully reversible on discontinuation. Critical safety point: discontinuation of denosumab leads to a rebound surge in bone resorption markers and a significantly elevated risk of multiple vertebral fractures (MVF) within 6–18 months. Transition to a bisphosphonate (typically zoledronic acid given 6 months after the last denosumab dose) is mandatory before or when stopping denosumab therapy.

5. Anabolic Therapy

Teriparatide (Forsteo) — recombinant human PTH 1-34, 20 mcg daily subcutaneous injection — is a bone-forming anabolic agent. The NEER NEJM 2001 trial demonstrated 65% reduction in vertebral fractures and 35% reduction in non-vertebral fractures versus placebo. Teriparatide increases bone formation markers and BMD significantly, particularly in the vertebral spine (trabecular bone). Treatment is licensed for 18–24 months (lifetime cumulative maximum) and must be followed by sequential antiresorptive therapy to preserve BMD gains. It is the preferred treatment for patients with multiple vertebral fractures, severe osteoporosis (T-score ≤−3.5), or failure/intolerance of antiresorptive agents.

Romosozumab (Evenity) — anti-sclerostin monoclonal antibody — has a dual mechanism: stimulating bone formation and inhibiting bone resorption simultaneously. The ARCH trial (NEJM, 2017) compared romosozumab followed by alendronate versus alendronate alone, demonstrating 48% reduction in new vertebral fractures, 27% reduction in clinical fractures, and 19% reduction in hip fractures at 24 months. The FRAME trial (NEJM, 2016) compared romosozumab followed by denosumab versus placebo followed by denosumab — 75% reduction in vertebral fractures at 12 months with romosozumab. An important caveat: ARCH identified a small but significant excess cardiovascular risk (heart attack and stroke) in the romosozumab arm; romosozumab is contraindicated within 12 months of MI or stroke and requires careful cardiovascular risk assessment.

6. Hormone Replacement Therapy (HRT)

For women under 60 years or within 10 years of menopause with significant menopausal symptoms, HRT prevents bone loss and reduces fracture risk comparably to bisphosphonates. The WHI trial fracture data support HRT for fracture prevention; it is particularly indicated in women with premature ovarian insufficiency (POI, menopause before 40). After discontinuation of HRT, bone loss accelerates — transition to antiresorptive therapy at HRT cessation should be considered in women with high fracture risk.

7. Selective Oestrogen Receptor Modulators (SERMs)

Raloxifene 60 mg daily reduces vertebral fracture risk by 30–50% (MORE trial) but does not reduce hip fracture risk and increases deep vein thrombosis risk. Its primary role is in postmenopausal women with osteoporosis and high breast cancer risk (SERMs reduce breast cancer risk by 50%). Bazedoxifene combined with conjugated oestrogen (Duavee) addresses both bone loss and menopausal symptoms without progestogen.

Effective osteoporosis management delivers profound individual and public health benefits:

• Dramatic fracture risk reduction: Antiresorptive agents reduce vertebral fracture risk by 40–70% and hip fracture risk by 20–40%. Anabolic agents (teriparatide, romosozumab) achieve up to 65–75% reduction in vertebral fractures — amongst the largest fracture risk reductions of any preventive intervention in medicine.
• Reduced hip fracture mortality: Hip fractures carry 20–30% one-year mortality in elderly patients. Zoledronic acid administered after hip fracture repair reduces subsequent mortality by 28% (HORIZON Recurrent Fracture Trial) — one of the few interventions demonstrated to reduce post-fracture mortality.
• Prevention of chronic pain and disability: Vertebral compression fractures cause acute and chronic back pain, height loss, progressive kyphosis, restrictive lung disease (from thoracic spine deformity), and significant reduction in quality of life. Effective treatment prevents incident and subsequent vertebral fractures, preserving spinal architecture.
• Preservation of independence: Hip fractures are the leading cause of permanent institutionalisation in older adults; fracture prevention directly preserves independence, mobility, and functional capacity.
• BMD improvement: Treatment increases lumbar spine BMD by 3–8% (antiresorptives) and 8–13% (anabolic agents) over 2–3 years, reducing the 'fracture threshold' risk.
• Cost-effectiveness: Treatment is highly cost-effective in patients at moderate-to-high fracture risk; bisphosphonates are now generic and very low cost, making them among the most economically efficient preventive medications available.

Osteoporosis medications have well-characterised side-effect profiles. Patients should understand these risks in context of the substantial fracture prevention benefit:

Oral bisphosphonates:

• Gastrointestinal: Oesophageal irritation, oesophagitis, and rarely oesophageal ulceration — mitigated by strict dosing instructions (fasting, full glass of water, remain upright 30–60 minutes). Contraindicated in patients with achalasia or oesophageal stricture.
• Atypical femoral fractures (AFF): A rare but recognised complication of long-term bisphosphonate use (>5 years). Risk is approximately 3–50 per 100,000 person-years; increases with duration. The absolute risk is tiny compared with hip fractures prevented by treatment. Patients should report thigh or groin pain — a prodrome of AFF. A drug holiday (treatment pause) after 3–5 years in lower-risk patients is recommended by most guidelines.
• Osteonecrosis of the jaw (ONJ): Extremely rare with oral bisphosphonate doses (1–69 per 100,000 patient-years). Risk is substantially higher with IV bisphosphonates at oncology doses (multiple times monthly). Dental review and any necessary invasive dental work should be completed before commencing bisphosphonate therapy; routine dental care can continue safely during treatment.

Intravenous zoledronic acid:

• Acute phase reaction: Flu-like symptoms, fever, myalgia, and bone pain in approximately 30% after the first infusion; typically lasting 24–72 hours. Subsequent infusions carry much lower risk. Pre-hydration and paracetamol/ibuprofen minimise severity. Severity decreases markedly with second and third infusions.
• Renal toxicity: Caution if eGFR <35 mL/min; contraindicated if eGFR <30 mL/min. Renal function should be checked before each annual infusion.

Denosumab:

• Hypocalcaemia: May occur after injection — calcium and vitamin D sufficiency must be confirmed before each dose. Particularly relevant in patients with renal impairment or malabsorption.
• Infections: Slightly increased risk of cellulitis and urinary tract infections (RANKL expressed in immune cells); patients should report signs of infection promptly.
• Rebound vertebral fractures: The most serious safety concern — multiple fractures may occur within 6–18 months of denosumab discontinuation. This requires mandatory sequential antiresorptive therapy and should be discussed thoroughly before initiating denosumab.
• ONJ and AFF: Similar low risk as with bisphosphonates at osteoporosis doses.

Teriparatide:

• Nausea, dizziness, and leg cramps; risk of hypercalcaemia (rare). Contraindicated in patients with prior radiation to the skeleton, Paget disease, unexplained alkaline phosphatase elevation, bone metastases, or hypercalcaemia. Not recommended in patients under 18 (open growth plates) or in pregnancy.

Romosozumab:

• Mild injection-site reactions. The ARCH trial identified excess cardiovascular events (MI, stroke) vs alendronate — romosozumab is contraindicated within 12 months of MI or stroke and requires careful cardiovascular risk stratification before use.

Osteoporosis is a lifelong chronic disease requiring sustained treatment and monitoring. The following framework guides follow-up:

BMD monitoring with DXA:

• Repeat DXA scan is recommended every 1–2 years at treatment initiation to confirm BMD response, then every 3 years on established stable therapy per NOGG (National Osteoporosis Guideline Group) UK recommendations.
• A significant BMD decline (>3–4%, exceeding the least significant change) on treatment should prompt reassessment: review adherence, calcium/vitamin D status, secondary osteoporosis causes, and possible treatment escalation.
• DXA should also assess for incident vertebral fractures on lateral vertebral fracture assessment (VFA) — a low-dose lateral spine image performed on the DXA table.

Bone turnover markers (BTMs):

• Serum CTX (C-terminal telopeptide of type I collagen — resorption marker) and P1NP (procollagen type I N-propeptide — formation marker) can be used to monitor treatment response and adherence at 3–6 months. A significant reduction in CTX confirms antiresorptive efficacy; a rise in P1NP with teriparatide confirms anabolic response.

Bisphosphonate drug holiday:

• After 3–5 years of oral bisphosphonate therapy (or 3 years of IV zoledronic acid), re-assessment of fracture risk is recommended. Patients at low-moderate ongoing risk may be offered a treatment pause ('drug holiday') of up to 2–3 years, during which residual bisphosphonate effect (alendronate has a very long skeletal half-life of approximately 10 years) continues to provide some fracture protection. Patients at high ongoing risk (prior hip/vertebral fracture, T-score <−2.5 at hip) should generally continue therapy.

Denosumab continuation planning:

• If denosumab is to be discontinued for any reason, an iv zoledronic acid infusion should be administered 6 months after the last denosumab injection to suppress the rebound in bone resorption. This is a firm recommendation from IOF, NOGG, and ESCEO — failure to plan the transition exposes patients to potentially serious rebound vertebral fractures.

Sequential anabolic-to-antiresorptive therapy:

• After completing 18–24 months of teriparatide or 12 months of romosozumab, immediate transition to antiresorptive therapy (denosumab or bisphosphonate) is mandatory to preserve the BMD gains achieved. Without sequential antiresorptive therapy, BMD rapidly returns toward pre-treatment levels, nullifying the benefit of anabolic treatment.

Treatment costs for osteoporosis vary substantially by agent, country, and healthcare system:

Generic bisphosphonates: The most cost-effective pharmacological option. Generic alendronate 70 mg weekly (brand: Fosamax) costs approximately USD 3–15/month (pharmacy price) in the USA; GBP 1–3/month in the UK. Risedronate is similarly priced as generic. These extremely low costs, combined with strong fracture evidence, make oral bisphosphonates the globally preferred first-line pharmacological intervention in cost-constrained healthcare systems.

IV zoledronic acid (Aclasta/Reclast): Annual infusion; cost of the drug is approximately USD 20–50 as generic. Hospital or clinic infusion administration fees add USD 100–500 per infusion. Total annual cost approximately USD 150–600 in most markets. Highly cost-effective given the once-yearly administration and strong evidence base.

Denosumab (Prolia): Two injections per year; branded cost approximately USD 800–1,200 per injection (USA) or GBP 180–200 per injection (NHS list price, though NHS pays negotiated discount). Annual cost approximately USD 2,000–3,000 privately; covered by NHS, Medicare Part D, and most private insurers with prior authorisation for patients meeting treatment criteria.

Teriparatide (Forsteo/Forteo): Daily injection for 18–24 months. Monthly cost approximately USD 2,500–3,500 in the USA (branded), though biosimilars (Terrosa, Movymia) and generics are significantly cheaper in European markets (USD 300–600/month). NHS prescribing requires documented severe osteoporosis criteria. Biosimilar availability is rapidly expanding globally, improving access and cost.

Romosozumab (Evenity): Monthly injection for 12 months. Among the most expensive osteoporosis agents — approximately USD 1,700–2,000 per injection in the USA (total course: USD 20,000–24,000). Coverage requires prior authorisation and documentation of high fracture risk and inadequacy of other agents.

DXA scanning: USD 100–300 per scan in the USA (often lower with insurance); GBP 50–100 privately in the UK (free on NHS when indicated). Typically required at diagnosis and every 1–3 years on treatment.

Medical tourism considerations: Bisphosphonate prescriptions and DXA services are available at low cost in India, Thailand, and Eastern Europe. Teriparatide biosimilars are significantly cheaper in India and Eastern Europe than in the USA or Australia.

Beyond standard pharmacotherapy, several alternatives and emerging approaches complement osteoporosis management:

Abaloparatide (Tymlos): A synthetic PTHrP analogue with anabolic bone-forming activity. The ACTIVE trial (NEJM, 2016) demonstrated 86% reduction in vertebral fractures and 43% reduction in non-vertebral fractures versus placebo over 18 months — superior to teriparatide in the head-to-head ACTIVExtend analysis. Licensed in the USA and some other countries; not yet available in UK/Europe. Followed by sequential antiresorptive therapy.

SERMs (Raloxifene): For postmenopausal women who cannot tolerate bisphosphonates, or who have concurrent high breast cancer risk. The MORE trial demonstrated 30–50% reduction in new vertebral fractures. Not effective for hip fracture prevention. Contraindicated in patients with personal or family history of DVT.

HRT/MHT for perimenopausal osteoporosis: Menopausal hormone therapy (oestrogen alone or combined with progestogen) effectively prevents postmenopausal bone loss and reduces fracture risk, with the benefit being lost within 1–2 years of discontinuation. It is appropriate first-line bone protection in younger postmenopausal women (<60 years or within 10 years of menopause), particularly when menopausal symptoms are also present.

Calcium and vitamin D optimisation: Maximising dietary calcium intake (dairy, fortified foods, leafy vegetables) to reach recommended daily intake (1,000–1,200 mg/day for post-menopausal women) and ensuring vitamin D sufficiency (serum level >50 nmol/L) supports the efficacy of all pharmacological treatments. Supplementation is targeted to deficient individuals.

Exercise programmes: Resistance training and impact exercise (walking, jogging, dancing) maintain BMD and reduce falls risk. The LIFTMOR trial demonstrated that high-intensity resistance and impact training (HIIT) improved lumbar spine and femoral neck BMD in postmenopausal women with low bone mass — a supervised programme of supervised resistance and jumping exercise was superior to low-intensity exercise for BMD outcomes.

Vertebroplasty and kyphoplasty: For acute painful osteoporotic vertebral compression fractures not responding to analgesics after 4–6 weeks, balloon kyphoplasty (BKP) or vertebroplasty (percutaneous cement injection into the fractured vertebra) may provide pain relief and height restoration. The VERTOS IV (sham-controlled RCT) supported vertebroplasty efficacy for acute fractures; the earlier INVEST and VERTOS II trials had conflicting results. BKP additionally corrects kyphosis. These are procedural options within the overall management plan, not alternatives to systemic osteoporosis therapy.